Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Indivior PharmaceuticalsINDV +0.17%75 EV-to-EBIT is 15.29 as of Jul. 24, 2026, which is 78% above its 10-year median of 8.58. GuruFocus rates INDV with a GF Score™ of 75/100 and a GF Value™ of $22.90 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 690 Drug Manufacturers companies, Indivior Pharmaceuticals ranks better than 51.01% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Indivior Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2026 was $4,053 Mil.
Indivior Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $335 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indivior Pharmaceuticals EV-to-EBIT Related Terms
Indivior Pharmaceuticals EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Indivior Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indivior Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Indivior Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Indivior Pharmaceuticals's EV-to-EBIT falls into.
Indivior Pharmaceuticals's current Enterprise Value is $5,122 Mil.
Indivior Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $335 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indivior Pharmaceuticals (INDV) has a EV-to-EBIT of 15.29 as of Jul. 24, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Indivior Pharmaceuticals and its competitors. This is 78% above median its historical median of 8.58. According to the industry distribution chart, Indivior Pharmaceuticals ranks #338 out of 690 companies in the Drug Manufacturers industry, placing it in the top 49%.
Is Indivior Pharmaceuticals' EV-to-EBIT too high?
Indivior Pharmaceuticals' current EV-to-EBIT of 15.29 is 78% above median its 10-year median of 8.58. The Drug Manufacturers industry median EV-to-EBIT is 15.46. Indivior Pharmaceuticals' value of 15.29 is 1.1% below this industry median. Based on the distribution chart, Indivior Pharmaceuticals ranks #338 out of 690 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Indivior Pharmaceuticals has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' EV-to-EBIT compare to KNSA and AMRX?
According to the Drug Manufacturers industry distribution chart, Indivior Pharmaceuticals ranks #338 out of 690 companies for EV-to-EBIT. This puts Indivior Pharmaceuticals in the upper half of its industry. The industry median EV-to-EBIT is 15.46. Indivior Pharmaceuticals' value of 15.29 is 1.1% below this benchmark. While the company's 10-year median is 8.58 vs. the industry median of 15.46, Indivior Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.46, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indivior Pharmaceuticals's current EV-to-EBIT of 15.29 is 1.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Indivior Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indivior Pharmaceuticals's current EV-to-EBIT is 15.29, which is 78% above median its own 10-year median of 8.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (INDV) is currently considered Significantly Overvalued. The stock's GF Value™ is $22.90, compared to a current price of $40.52 — trading 76.9% above its estimated fair value. The current EV-to-EBIT is 15.29, which is 78% above median its 10-year median of 8.58 and 1.1% below the Drug Manufacturers industry median of 15.46. Indivior Pharmaceuticals' overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Indivior Pharmaceuticals (INDV), the current EV-to-EBIT is 15.29 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indivior Pharmaceuticals (INDV) Overvalued in 2026?
Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued.
The current stock price of $40.52 is trading 76.9% above its estimated GF Value™ of $22.90.
GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for INDV:
EV-to-EBIT: 15.29 (78% above median its 10-year median of 8.58)
GF Value™: $22.90 vs. price of $40.52 (76.9% above fair value)
Industry Position: 1.1% below the Drug Manufacturers median (#338 of 690)
No single metric tells the full story. See the INDV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
75GF Score
Get the complete analysis for INDV
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INDV has been successfully added to your 
